ATNM issues catapulting biotech news. Read more.

This is a paid advertisement provided to our customers. Although we have sent you this email, Schaeffer's Investment Research does not endorse this product nor is it responsible for the content of this ad. Furthermore, we make no guarantee or warranty about what is advertised below.

Actinium Pharmaceuticals, Inc. (ATNM) Moving a Step Closer to Targeting Cancer Rating: BUY Actinium Pharmaceuticals, Inc. 757 Third Avenue, 21st Floor New York, NY 10017 Phone: (646) 459-4201 www.actiniumpharma.com Published November 18, 2015 Submits Iomab™-B Investigational New Drug ("IND") application with U.S. Food and Drug Administration. Prepares for initiation of Phase 3 Clinical Study in refractory and relapsed Acute Myeloid Leukemia ("AML") patients needing Bone Marrow Transplants ("BMT"). COMPANY OVERVIEW AND PRODUCTS: Actinium Pharmaceuticals, Inc. (NYSE MKT: ATNM), ("the company") is a biopharmaceutical company that develops innovative targeted payload immunotherapeutics for the treatment of advanced cancers. The company develops cancer drugs, primarily using its Alpha Particle Immunotherapy Technology ("APIT") platform. This patented technology combines monoclonal antibodies (mAB) for targeting specific types of cells with alpha emitting radioisotopes, to precisely target and kill cancerous cells. The Company's products are based on patented technology co-developed with Memorial Sloan Kettering Cancer Center (MSKCC). �The company has developed drugs for treating leukemia, metastatic colorectal and prostate cancers, antiangiogenesis (prevention of blood supply to and growth of many solid cancers), and bone marrow ablation (a treatment for leukemias, lymphomas and multiple myeloma). The company has two clinical stage products, Actimab™-A for acute myeloid leukemia ("AML"), which was co-developed with MSKCC, and Iomab™-B for bone marrow conditioning before a hematopoietic stem cell transplant (HSCT), which was developed by Fred Hutchinson Cancer Center. Over 300 patients have been treated in multiple Phase 1 and Phase 2 clinical trials for Actimab™-A and Iomab™-B. The company's product pipeline contains additional treatments focused on antiangiogenesis, metastatic colorectal cancer, and prostate cancer. The market potential for the company's cancer drugs is illustrated below.1 Market Potential for Lead Products # Cancer Indication Cases/Yr. in target market1 Target Population Worldwide Market Potential ($mm)2 1st HSCT (Bone Marrow) 48,000 48,000 $4,100 2nd Acute Myeloid Leukemia (AML) 41,600 24,000 $920 3rd Glioblastoma Multiforme (GBM) 26,500 26,500 $1,100 4th Prostate Cancer (metastatic) 591,000 298,455 $5,959 5th Metastatic Colorectal Cancer 536,000 241,200 $4,824 Target market indicates USA, EU and Japan Market Potential calculated based on assumption that Actinium products for solid cancer indications will be priced at $20,000 per treatment; HSCT preparation product will be priced at $85,000 per treatment; AML product will be priced at $60,000 per treatment; and GBM product will be priced at $60,000 per treatment. Estimates based on independent third party research and adjusted for lower pricing in non-US markets. RECENT DEVELOPMENTS: On Tuesday, November 17, 2015, the company announced that it had successfully submitted an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) for Iomab-B™, a radioimmunotherapeutic that conditions Acute Myeloid Leukemia (AML) patients for a Hematopoietic Stem Cell Transplant ("HSCT"), commonly referred to as a Bone Marrow Transplant (BMT). �This announcement was ahead of the company's previous guidance for a year-end IND application filing. Pending the FDA's acceptance of the IND filing, the company will initiate a single, pivotal Phase 3 clinical study in refractory and relapsed AML patients over the age 55. The company anticipates this Phase 3 study starting in 2016, and has worked to eliminate previous manufacturing issues. According the company's Executive Chairman, Sandesh Seth, "this much anticipated regulatory filing is an important one that marks the first step in Actinium's transition to a later development stage biopharmaceutical company. �As we prepare for the pivotal Phase 3 clinical trial for Iomab-B™ in 2016, we have added key members to our executive, regulatory and clinical operations teams, and will continue to add selectively. �This strengthening of the company will enable us to meet our goals of efficient execution of not only the Iomab-B™ program but also of the Actimab-A™ Phase 2 trial planned for early 2016, as well as other pre-clinical and clinical programs expected for next year." Iomab-B™ will be used in preparing patients for hematopoietic stem cell transplantation (HSCT), which is the fastest growing hospital procedure in the U.S. ��The company established an agreement with the FDA that the path to a Biologics License Application ("BLA") submission could include a single, pivotal Phase 3 clinical study, if it is successful. �The population in this "two arm", randomized, controlled, multicenter trial will be refractory and relapsed Acute Myeloid Leukemia (AML) patients over the age of 55. �The trial size was set at 150 patients with 75 patients per arm. �The primary endpoint in the pivotal Phase 3 trial is durable complete remission, defined as a complete remission lasting at least 6 months and the secondary endpoint will be overall survival at one year. It is important to note that there are currently no effective treatments approved by the FDA for AML in this patient population, and there is no defined standard of care. �In 2015, the U.S. National Cancer Institute ("NCI") estimates that 20,800 cases of AML will be diagnosed in the United States.2 An estimated 10,500 individuals will be killed by AML in 2015.3 Iomab-B™ has completed several physician sponsored clinical trials examining its potential as a conditioning regimen prior to HSCT in various blood cancers, including the Phase 1/2 study in relapsed and/or refractory AML patients. �The results of these studies in over 300 patients have demonstrated the potential of Iomab-B to create a new treatment paradigm for bone marrow transplants by: Expanding the pool to ineligible patients who do not have any viable treatment options currently; Enabling a shorter and safer preparatory interval for HSCT; Reducing post-transplant complications; Showing a clear survival benefit including curative potential. Iomab-B™ is a radioimmunoconjugate consisting of BC8, a novel murine monoclonal antibody, and iodine-131 radioisotope. �BC8 has been developed by the Fred Hutchinson Cancer Research Center to target CD45, a pan-leukocytic antigen widely expressed on white blood cells. �This antigen makes BC8 potentially useful in targeting white blood cells in preparation for hematopoietic stem cell transplantation in a number of blood cancer indications, including acute myeloid leukemia (AML), chronic myeloid leukemia ("CML"), acute lymphoblastic leukemia ("ALL"), chronic lymphocytic leukemia ("CLL"), Hodgkin's disease ("HD"), Non-Hodgkin lymphomas ("NHL") and multiple myeloma ("MM"). �When labeled with radioactive isotopes, BC8 carries radioactivity directly to the site of cancerous growth and bone marrow while avoiding effects of radiation on most healthy tissues. OUTLOOK: While the company has not recorded any revenues from sales of any of its immunotherapeutics, the company has a relatively strong balance sheet.�As of September 30, 2015, the company had approximately $24,762,045 in cash, as compared to approximately $6,706,802 in cash on December 31, 2014. The company's total liabilities were approximately $2,155,294 for the period ended September 30, 2015, as compared to approximately $9,491,616 on December 31, 2014. BOTTOM LINE: As with an investment in many smaller biotechnology companies that are "pre-revenue", an investment in the shares of Actinium Pharmaceuticals, Inc. continues to be a "high risk, high reward" situation. The company will continue to report no revenue until its products receive FDA approval and are in the marketplace. Additionally, the company's share price is likely to remain highly volatile and will react to news releases, such as announcements of year end results for 2015, and results of the Phase 2 and Phase 3 studies that that are about to begin. Following this evening's announcement, I continue to believe that the rewards outweigh the foreseeable risks, and I reiterate my Buy recommendation. A more detailed report on the company will be released before the market open on Thursday, November 19, 2015. SOURCES: 1 http://www.actiniumpharma.com/wp-content/uploads/ATNM-Corporate-Profile1.pdf 2 http://www.bionapcfa.com/2015/11/actinium-pharmaceuticals-platform.html?m=1 3 Ibid. IMPORTANT NOTICE AND DISCLAIMER: This sponsored advertising of Actinium Pharmaceuticals, Inc. does not purport to provide an analysis of any company's financial position, operations or prospects and this is not to be construed as a recommendation, or an offer or solicitation to buy or sell any security. The "Company" featured in this issue, appears as paid advertising, paid by a third party to provide public awareness for Actinium Pharmaceuticals. This Report has used outside research and writers using public information to create this advertisement. The third party owns no shares of Actinium Pharmaceuticals. Although the information contained in this advertisement is believed to be reliable, there can be no warranties as to the accuracy of any of the content herein and the publishers accept no liability for how readers may choose to utilize the content. Readers should perform their own due-diligence, including consulting with a licensed, qualified investment professional or analyst. Further, readers are strongly urged to independently verify all statements made in this advertisement and perform extensive due diligence on this or any other advertised company. The publishers are not offering securities for sale. An offer to buy or sell can be made only with accompanying disclosure documents and only in the states and provinces for which they are approved. Many states have established rules requiring the approval of a security by a state security administrator. Check with http://www.nasaa.org or call your state security administrator to determine whether a particular security is licensed for sale in your state. Many companies have information filed with state securities regulators and many will supply investors with additional information on request. The advertiser anticipates managing a total production budget of $350,000 for this online advertising effort and will retain any amounts over and above the cost of production, copywriting services, mailing and other distribution expenses, as a fee for its services. Specific financial information, filings, and disclosures as well as general investor information about publicly traded companies like Actinium Pharmaceuticals, advice to investors and other investor resources are available at the Securities and Exchanges Commission website www.sec.gov and www.nasd.com. Any investment should be made only after consulting with a qualified investment advisor and after reviewing the publicly available financial statements of and any other information about the company and verifying that the investment is appropriate and suitable. Investing in securities is highly speculative and carries a great deal of risk especially as to new companies with limited operations and no history of earnings. The information contained herein contains forward-looking information within the meaning of section 27a of the Securities Act of 1993, as amended, and section 21e of the Securities Exchange Act of 1934, as amended, including statements regarding expected growth of the featured company. In accordance with the safe harbor provisions of the Private Securities Litigation Reform Act, statements contained herein that look forward in time, which include everything other than historical information, involve risks and uncertainties that may affect the Company's actual results of operations. Forward-looking statements are based upon expectations, estimates and projections at the time the statements are made and involve risks and uncertainties that could cause actual events to differ materially from those anticipated. Forward-looking statements may be identified through the use of words such as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should, or might occur. Any statements that express or involve predictions, expectations, beliefs, plans, projections, objectives, goals or future events or performance may be forward-looking statements. In accordance with the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, the publisher notes that statements contained herein that look forward in time, which include other than historical information, involve risks and uncertainties that may affect the company's actual results of operations. Factors that could cause actual results to differ include, but are not limited to, the size and growth of the market for the company's products and services, regulatory approvals, the company's ability to fund its capital requirements in the near term and the long term, pricing pressures and other risks detailed in the company's reports filed with the Securities and Exchange Commission.

This is a PAID ADVERTISEMENT provided to our customers. Although we have sent you this email, Schaeffer’s Investment Research does not endorse this product nor is it responsible for the content of this ad. Furthermore, we make no guarantee or warranty about what is advertised above. Your privacy is very important to us, If you wish to be excluded from future notices, do not reply to this message. Instead, please go to the following address:  http://ads.schaeffersresearch.com/schaeffers-unsubscribe-partner/?o=357130&e=IGNOBLE.EXPERIMENT@arconati.us DISCLAIMER: In accordance with Section 17(b) of the Securities Act of 1933, you are hereby advised that Schaeffer’s Investment Research, Inc. "Schaeffer’s" is receiving a fee of over $1000.00 in cash, from an independent third party as compensation for the distribution of this advertisement. Schaeffer’s has not determined if the statements and opinions of the advertiser are accurate, correct or truthful. The purpose of this advertisement, like any advertising, is to provide publicity for the advertising company, its products or services. You should not rely on the information presented; you should do independent research to form your own opinion and decision. Information contained in our disseminated emails does not constitute investment, legal or tax advice upon which you should rely. The purchase of high-risk securities may result in the loss of your entire investment. Advertisements received by you are not a solicitation or recommendation to buy securities of the advertised company. An offer to buy or sell securities can be made only by a disclosure document that complies with applicable securities laws and only in the States or other jurisdictions in which the security is eligible for sale. Advertisements distributed through disseminated emails are not disclosure documents. If you are considering purchasing any securities of an advertised company, you should call your State Securities Administrator to determine if the security may be sold in your State. Many companies have information filed with State securities regulators who may be able to supply you with additional information. You also should read and review, if and to the extent available, any information concerning an advertised company available at the web sites of the U.S. Securities and Exchange Commission (the "SEC") at http://www.sec.gov and the Financial Industry Regulatory Authority (the "FINRA") at http://www.FINRA.org. We also strongly recommend that you read the SEC advisory to investors concerning Internet Stock Fraud at http://www.sec.gov/consumer/cyberfr.htm, as well as related information published by the NASD on how to invest carefully. You are responsible for verifying all claims and conducting your own due diligence. You agree and acknowledge that any hyperlinks to the website of (1) an advertised company, (2) the party issuing or preparing the information for the advertised company, or (3) other information contained in our disseminated emails is provided only for your reference and convenience. We are not responsible for the accuracy or reliability of these external sites, nor are we responsible for the content, advertising, opinions, products or other materials on external sites or information sources. If you use, act upon or make decisions in reliance on information contained in any disseminated email or any hyperlink, you do so at your own risk and agree to hold us, our officers, directors, shareholders, affiliates and agents harmless. You acknowledge that you are not relying on us, and we are not liable for, any actions taken by you based on any information contained in any disseminated email or hyperlink. You also acknowledge that we are not an investment advisory service, a broker-dealer or an investment adviser. You acknowledge that you will consult with your own advisers regarding any decisions as to any advertised company.